Ultragenyx Pharma (RARE) Misses Q3 EPS by 11c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.64), $0.11 worse than the analyst estimate of ($1.53).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
• Snowflake soars 20% on earnings beat and raised guidance
• Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance